Tatiana Schlossberg, the granddaughter of President John F. Kennedy, has revealed she is living with terminal cancer after being diagnosed with acute myeloid leukemia last year. In a personal essay, she expressed fears about her limited time with her young children and criticized policy decisions supported by her cousin, Health and Human Services Secretary Robert F. Kennedy Jr. Her announcement coincided with the anniversary of her grandfather’s assassination.

A Personal Revelation Shared on a Historic Anniversary

Tatiana Schlossberg confirmed on Saturday that she has been diagnosed with a terminal form of acute myeloid leukemia (AML), a fast-progressing cancer that affects the blood and bone marrow. The disclosure came in an essay published in The New Yorker on the sixty-second anniversary of her grandfather’s assassination, a date that continues to hold deep significance for the Kennedy family.

Schlossberg, an environmental journalist and author, is the daughter of Caroline Kennedy—currently U.S. Ambassador to Australia—and Edwin Schlossberg. She wrote that her diagnosis came in May 2024, shortly after the birth of her second child. Routine blood work revealed severely elevated white blood cell counts, prompting further tests that confirmed a rare genetic mutation associated primarily with older AML patients.

According to the American Cancer Society, AML is an aggressive cancer requiring rapid treatment. Younger patients tend to have better survival prospects than older ones, but rare gene mutations can complicate outcomes. Schlossberg explained that the nature of her mutation and the speed at which her cancer progressed meant her doctors prepared her early for difficult news.

Intensive Treatments and Limited Options

Since her diagnosis, Schlossberg has undergone multiple rounds of chemotherapy, two stem-cell transplants, and participation in clinical trials. Her first transplant used stem cells donated by her sister, while the second came from an unrelated donor. Despite these interventions, her care team has struggled to control the cancer’s progression.

During a recent experimental treatment, one of her doctors gave a blunt prognosis: he believed he could keep her alive for “a year, maybe.” Schlossberg wrote about the moment with heartbreaking clarity, acknowledging both the gratitude she felt for the medical teams trying to save her life and the fear that accompanies a terminal diagnosis.

AML, particularly forms with complex genetic markers, often requires a combination of chemotherapy, immunotherapy, and specialized transplants. Clinical trials are sometimes the only remaining avenues when standard therapies fail. Schlossberg’s account underscores the precarious nature of such treatments and the uncertainty faced by patients who depend on emerging scientific advances.

Concerns Over RFK Jr.’s Stance on Medical Research

In her essay, Schlossberg also raised alarm about policies supported by her cousin, Health and Human Services Secretary Robert F. Kennedy Jr. She argued that some of his positions—and the budget decisions he has endorsed—could jeopardize funding for research that directly benefits cancer patients like herself.

She cited, in particular, his support for cutting nearly half a billion dollars from mRNA vaccine research. While widely associated with COVID-19 vaccine development, mRNA technology has broader potential applications, including in targeted cancer therapies and individualized immunotherapies. According to the U.S. National Institutes of Health, mRNA-based cancer treatments are among the most promising areas of ongoing research.

“As I spent more and more of my life under the care of doctors, nurses, and researchers striving to improve the lives of others,” she wrote, “I watched as Bobby cut nearly a half billion dollars for research into mRNA vaccines, technology that could be used against certain cancers.”

Caroline Kennedy, Schlossberg’s mother, has previously urged senators to oppose RFK Jr.’s nomination, arguing that his long-standing skepticism of vaccines and medical science could undermine federal health and research agencies. Schlossberg’s essay adds a personal dimension to that criticism, linking budget decisions to potential consequences for patients.

Fears for the Future and the Weight of Family History

Schlossberg’s writing conveyed profound sadness about her children’s future memories, or lack thereof. She shares two young children with her husband, George Moran, and expressed anguish over the possibility that they may grow up without remembering her. She described feeling “cheated” of the life she envisioned—one defined by parenthood, partnership, and long-term plans abruptly disrupted by illness.

She also reflected on the emotional burden placed on her parents and siblings, who try to shield her from their grief even as they navigate their own. “For my whole life, I have tried to be good, to be a good student and a good sister and a good daughter,” she wrote. “Now I have added a new tragedy to her life, to our family’s life, and there’s nothing I can do to stop it.”

The Kennedy family has endured decades of loss, and Schlossberg’s admission adds another deeply personal chapter to a long, public history of tragedy. Yet much of her essay focused less on family legacy and more on the universal experiences of fear, hope, and uncertainty that accompany terminal illness.

A Call to Support Medical Research and Compassionate Policy

While Schlossberg’s essay centered on her personal story, it also served as a broader appeal to preserve and strengthen scientific research efforts. She praised the doctors, nurses, and researchers who have treated her and supported her family over the past year. Their dedication, she wrote, reminded her of the profound value of medical innovation and the importance of policies that protect investments in health research.

Her message aligns with long-standing calls from global institutions such as the World Health Organization and the U.S. National Cancer Institute, both of which highlight the importance of sustained funding for emerging cancer treatments, clinical trials, and next-generation therapies.

Although her prognosis remains uncertain, Schlossberg said she hopes her experience encourages others to recognize how policy decisions impact patients who depend on scientific advancements. Her essay closed on a note of reflection—an acknowledgment of the life she cherishes and the love that sustains her, even as she confronts limited time.

Source: AP News – JFK’s granddaughter reveals terminal cancer diagnosis and criticizes her cousin RFK Jr.

The post JFK’s Granddaughter Reveals Terminal Cancer Diagnosis and Criticizes RFK Jr.’s Policies appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Lung cancer is often linked in our minds with smoking — but what happens when people who have never smoked start getting diagnosed more and more? The surprising rise of lung cancer among non-smokers is turning heads in the medical world, challenging old assumptions and raising important questions about causes, risks, and treatment.

Martha’s Story: A Wake-Up Call

Take Martha’s experience. At 59, she never considered herself a smoker — sure, she’d occasionally lit a cigarette at parties, but nothing regular. So when her cough changed and her mucus thickened, she thought it was just a flare-up from a rare lung disorder she already had. Doctors initially agreed it was nothing to worry about.

But after an X-ray revealed a shadow on her lung, things quickly escalated. A CT scan and bronchoscopy confirmed a tumour. Four months after she first mentioned symptoms, Martha was diagnosed with Stage IIIA lung cancer. The tumour had invaded nearby lymph nodes but hadn’t spread further.

“It was a total shock,” Martha says. And her story isn’t unique.

Lung Cancer Beyond Smoking: A Growing Global Concern

Lung cancer remains the world’s most common cancer and the deadliest, with around 2.5 million new cases and 1.8 million deaths in 2022 alone. While smoking still accounts for the majority of cases, smoking rates have dropped in many parts of the world over the last decades. At the same time, lung cancer diagnoses among people who have never smoked now make up 10 to 20% of cases — and that percentage is rising.

Dr. Andreas Wicki, an oncologist from the University Hospital Zurich, explains, “Lung cancer in never-smokers is emerging as a distinct disease, with unique molecular features that affect treatment and outcomes.” Interestingly, younger lung cancer patients—those in their 30s or 40s—are more likely to be non-smokers, and the cancer type tends to differ as well.

A Different Type of Lung Cancer

The kind of lung cancer common among smokers—squamous cell carcinoma—used to dominate until the mid-20th century. But in never-smokers, nearly all lung cancers are adenocarcinomas, which originate in mucus-producing cells.

The catch? Adenocarcinomas are often diagnosed late because small tumors don’t cause obvious symptoms. Persistent cough, chest pain, and breathlessness only show up once the tumour grows or spreads. “Because most people associate lung cancer with smoking, non-smokers may dismiss early warning signs, delaying diagnosis until advanced stages,” says Wicki.

Why Are Women More Affected?

Non-smoking women are more than twice as likely as men who never smoked to develop lung cancer. This may be linked to differences in lung anatomy, environmental exposures, and genetics. A key player is a mutation called EGFR, which is especially common in women and notably in Asian women.

Scientists suspect female hormones and genetic variants affecting estrogen metabolism might explain this higher incidence, though research is ongoing.

The Role of Genetics: Driver Mutations and Targeted Therapies

Cancer cells in non-smokers often carry “driver mutations” that fuel tumour growth. EGFR mutations are the best-known example. Once these mutations were identified, drug companies developed targeted therapies—EGFR inhibitors—that block the mutant protein’s activity.

“About 20 years ago, these drugs showed great promise,” Wicki says. “Many patients responded well, but resistance often developed, leading to relapse.” Newer generations of these drugs are now improving survival, with some patients living more than 10 years after diagnosis—an incredible leap from the less-than-12-month survival rates seen two decades ago.

What’s Causing Lung Cancer in Non-Smokers?

Without smoking as a cause, what else is driving lung cancer? Experts point to a mix of environmental and genetic factors:

• Radon exposure and second-hand smoke
• Indoor air pollution from cooking fumes and burning wood or coal, especially in poorly ventilated homes
• Outdoor air pollution, which is now recognized as the second leading cause of lung cancer worldwide after smoking

Air pollution—specifically tiny particles called PM2.5 found in vehicle exhaust and fossil fuel smoke—has been linked to lung cancer, particularly among those with EGFR mutations.

How Air Pollution May Trigger Lung Cancer

New research from the Francis Crick Institute in London sheds light on how air pollution might kickstart lung cancer in non-smokers carrying the EGFR mutation. Instead of directly mutating DNA like cigarette smoke, PM2.5 particles activate immune cells called macrophages. These cells release signals that “wake up” dormant mutant cells in the lungs, pushing them to grow into tumors.

This discovery opens exciting possibilities for new ways to prevent lung cancer by targeting the lung environment, not just the cancer cells themselves.

The Bigger Picture: Air Pollution’s Growing Impact

Air pollution’s connection to lung cancer isn’t new—it was mentioned as a possible cause as early as 1950. Yet for decades, anti-smoking policies dominated lung cancer prevention.

Today, 99% of the world’s population lives in areas exceeding the World Health Organization’s air quality guidelines. Rising pollution in places like India and China means the lung cancer burden from environmental factors may grow.

In the US, wildfires are causing spikes in PM2.5 levels, linked to increased lung cancer cases. Experts agree that shifting away from fossil fuels is critical not only for climate change but also for lung health.

Looking Ahead: Changing Perceptions and Hope

As treatments improve, lung cancer in never-smokers is becoming more manageable, challenging the stereotype that lung cancer is a smoker’s disease or a death sentence.

Martha, now almost three years post-diagnosis, takes an EGFR inhibitor. It’s not easy—side effects like fatigue and skin issues make daily life challenging—but the drug works. “The fatalistic view of lung cancer is changing, and that’s a hopeful sign,” she says.

With ongoing research and growing awareness of environmental risks, the future may hold better prevention and longer survival for those diagnosed with this mysterious form of lung cancer.

Source: BBC – The mystery rise of lung cancer in non-smokers

The post The Rise of Lung Cancer in Non-Smokers: What You Need to Know appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Michael Bolton is facing one of the toughest challenges of his life — and he’s opening up with honesty and resilience.

The 72-year-old Grammy-winning singer revealed in a recent People interview that he was diagnosed with glioblastoma, an aggressive and incurable form of brain cancer, in late 2023. The diagnosis followed emergency surgery to remove a brain tumor in December. Just a month later, Bolton had to undergo a second brain surgery due to an infection.

Despite the difficult journey, Bolton has continued to fight with determination and optimism. He completed both chemotherapy and radiation treatments in October 2024 and now undergoes regular MRIs every two months to monitor for any recurrence.

“Succumbing to the challenge is not an option,” Bolton said. “You’re really quickly drawn into a duel. I guess that’s the way you find out what you’re made of.”

According to the Cleveland Clinic, glioblastoma is the most common malignant brain tumor in adults and grows rapidly, though it rarely spreads beyond the brain and spinal cord. The prognosis is often grim — without treatment, life expectancy can be less than six months. Still, treatments can help slow the progression and manage symptoms.

Bolton admitted the physical and emotional toll has been significant. He’s experienced challenges with short-term memory, speech, and mobility, but he hasn’t let it define him. Instead, he’s focused on recovery and maintaining strength — with the help of a personal trainer and voice therapist.

More than anything, the singer finds strength in his support system.

“Just to know that you’re not alone going through it is a big deal,” he said. “It actually helps people to know. It reminds them that they’re not alone.”

Bolton’s family has been by his side throughout his battle, and he’s using this time to deepen those relationships, especially with his children. He’s more reflective than ever about the legacy he wants to leave behind.

“How do I give things that they can take forward? Life lessons, love, any kind of validation — I want to be on the right side of that so they feel great about who they are,” he shared.

Rather than focus on the odds or statistics, Bolton is choosing to live in the moment and remain hopeful.

“It’s unthinkable for it to be okay not to make the most of your life,” he said. “You have to be a cheerleader for yourself.”

His daughter, Taryn Bolton, echoed that sentiment:

“We’re in this together, and that’s it.”

As he continues his journey, Bolton hopes his openness helps others facing similar battles feel less alone — and more empowered to keep fighting.

Source: Today – Michael Bolton reveals glioblastoma diagnosis: ‘You find out what you’re made of’

The post Michael Bolton Reveals Brain Cancer Diagnosis and His Fight to Stay Strong appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

King Charles III was seen waving to well-wishers in central London on Friday before departing for his country estate in western England. This public appearance came just a day after the 76-year-old monarch was briefly hospitalized due to side effects from a scheduled cancer treatment.

While Buckingham Palace reassured the public that the king’s condition remains stable, the incident served as a stark reminder that Charles continues to undergo treatment for an undisclosed form of cancer diagnosed in early 2024. Over the past year, his health has largely faded from public consciousness as he resumed royal duties, attending key events such as the D-Day commemorations in France, the State Opening of Parliament, and a significant nine-day visit to Australia and Samoa.

Despite his medical condition, Charles has remained committed to his constitutional responsibilities, regularly reviewing government papers and meeting with the prime minister.

On Thursday morning, King Charles attended a scheduled cancer treatment at the London Clinic, a private hospital in central London where he has been receiving medical care since his diagnosis. Following the procedure, the king experienced temporary side effects that required brief hospitalization for observation.

According to a Buckingham Palace statement:

“Following scheduled and ongoing medical treatment for cancer this morning, the king experienced temporary side effects that required a short period of observation in hospital. His majesty’s afternoon engagements were therefore postponed.”

After being discharged, Charles returned to Clarence House, where he continued reviewing official documents and making calls. Queen Camilla did not accompany him to the hospital.

The palace further stated:

“His majesty would like to send his apologies to all those who may be inconvenienced or disappointed as a result.”

Despite the brief hospitalization, King Charles is expected to continue with his royal engagements, including a scheduled state visit to Italy in early April.

The palace has taken a more transparent approach to Charles’ health, acknowledging that speculation would arise if he had to cancel engagements unexpectedly.

This marks a shift from past royal practices. When Queen Elizabeth II began missing public appearances toward the end of her life, the palace only cited “mobility issues” without providing further details. Similarly, Charles’ grandfather, King George VI, had lung cancer before his death in 1952, but the public—and reportedly the king himself—were kept in the dark about the severity of his condition.

By contrast, King Charles has chosen to be more open, a decision that has been widely praised.

Health officials have credited the king’s public acknowledgment of his prostate treatment in early 2024 with encouraging thousands of men to undergo prostate exams. His transparency has also fostered a deeper connection with the public, demonstrating that even a monarch faces personal health challenges.

Despite his illness, Charles remains one of the most active members of the royal family. In 2024, he undertook 372 public engagements, making him the second-busiest royal after his sister, Princess Anne, who attended 474 events.

Charles has long been known as a workaholic. Queen Camilla has previously noted that he “won’t slow down and won’t do what he’s told.” During a literary festival in July, she remarked that he was “doing fine” but had ignored advice to reduce his workload.

Royal biographer Robert Hardman, author of Charles III: New King, New Court, the Inside Story, noted that the king’s packed schedule has made many forget he is battling cancer.

“We’ve seen him go back to normal,” Hardman told the BBC. “I think this is a reminder that this is a head of state undergoing treatment for cancer, because I think a lot of us tended to forget it.”

While King Charles remains committed to his duties, his recent hospitalization serves as a sobering reminder that he is still a cancer patient. His openness about his health has endeared him to the public and highlighted the challenges of balancing royal responsibilities with medical treatment. As he continues his duties, the world will be watching to see how he navigates this chapter of his reign.

Source: AP News – King Charles III’s brief hospital stay reminds UK that monarch is still a cancer patient

The post King Charles III’s Health Reminder: A Brief Hospital Stay Sparks Concern appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

China’s DeepSeek Sparks a Wave of Innovation Beyond Big Tech

China’s rise in innovation isn’t limited to technology—it’s quietly transforming the pharmaceutical industry as well. In a groundbreaking development, Akeso, a little-known Chinese biotech company, has delivered a lung cancer drug that outperformed the world’s best-selling medicine, Keytruda by Merck.

A Game-Changing Discovery

In September 2024, clinical trials conducted in China revealed that Akeso’s drug, Ivonescimab, delivered superior results compared to Keytruda, which has amassed over $130 billion in global sales.

Clinical Trial Results:

• Ivonescimab: Patients went 11.1 months before tumor progression.
• Keytruda: Patients saw progression in just 5.8 months.

The results, unveiled at the World Conference on Lung Cancer, marked a historic moment for Chinese biotech—but at the time, it went largely unnoticed outside the industry.

Stock Surge & Global Attention

That changed when DeepSeek, another Chinese firm, made headlines with its own medical breakthroughs, drawing global attention to China’s growing pharmaceutical power.

In early September, shares of Summit Therapeutics, Akeso’s U.S. partner, more than doubled, reaching record highs. The California-based company had secured the exclusive rights to commercialize Ivonescimab in North America and Europe, making it a major player in the global market.

“We believe the Chinese biotech industry will play an important role globally,” said Michelle Xia, CEO of Akeso, in an interview with BiotechTV.

Akeso also expressed its excitement in a statement to CNN, highlighting that its innovation comes from a deep understanding of disease biology and protein engineering, as well as China’s fast-paced development process and highly skilled talent pool.

China’s Biotech Boom: From Copycats to Innovators

For decades, China’s pharmaceutical industry focused on producing “me-too” drugs, essentially low-cost replicas of existing medications. That began to change over the last 10 years, with Chinese biotech firms now producing cutting-edge medications that compete with Western pharmaceutical giants.

Major Licensing Deals with Western Firms:

• AstraZeneca & CSPC Pharmaceutical Group – $1.92 billion deal for cardiovascular medication.
• Merck & Hansoh Pharmaceutical – $2 billion partnership for an experimental weight-loss drug.

Experts say the shift is undeniable.

“People knew China’s biotech industry was growing fast, but few saw it as a real threat to top U.S. innovators,” said Rebecca Liang, pharmaceuticals analyst at AB Bernstein. “Now, with next-generation drugs like Ivonescimab, that threat is getting real.”

China’s Rise as a Global Innovation Hub

According to HSBC Qianhai Securities, China has rapidly become an innovation hotspot for biotech:

Key Industry Growth Stats:

• Licensing deals: 46 in 2017 → 200+ in 2023
• Total deal value: $4 billion (2017) → $57 billion (2023)
• Large pharmaceutical transactions (above $50M) grew 30% in 2024 compared to 2023.

“Chinese biotech firms’ research capabilities and efficiency are catching up fast,” said Cui Cui, Managing Director of Healthcare Research at Jefferies. “Government support, foreign investment, and local talent are all fueling this growth.”

Doubts at Home: Can Chinese Drugs Win Over Local Patients?

While Akeso’s drug is making waves globally, many Chinese citizens remain skeptical about domestic pharmaceuticals.

Concerns over generic drug quality recently sparked a public outcry, leading to an official investigation into China’s pharmaceutical industry. The country’s health regulator later defended the safety of domestic medications, but doubts persist.

Public Opinion in China:

• Gu Zhihao, a Beijing resident: “To be honest, I prefer the more expensive imported medicine. After all, you get what you pay for.”
• US Investors & FDA Concerns: The FDA has previously rejected drugs developed in China, citing trial methodology concerns.

What’s Next for Akeso & Ivonescimab?

While China’s drug regulator has approved Ivonescimab for some lung cancer patients, it will take years before it reaches the U.S. market.

Upcoming Global Trial (2025): A new international clinical trial is planned, which could validate Ivonescimab’s efficacy on a global scale. If successful, it would cement China’s role as a biotech leader and challenge Western dominance in cancer treatment.

Conclusion: A New Era in Global Pharma

China’s biotech industry is no longer just catching up—it’s now a serious contender in global drug development. If companies like Akeso and DeepSeek continue delivering breakthrough treatments at lower costs, the entire pharmaceutical landscape could shift dramatically.

Is the world ready for Chinese-made, best-in-class medicines? The success of Ivonescimab may be the first major test.

Source

The post Little-Known Chinese Company Shocks Pharma Industry with Breakthrough Drug appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Physical Activity Could Improve Survival Rates After Diagnosis

A new study suggests that exercise may significantly extend the lives of people diagnosed with colon cancer—potentially allowing them to live as long as those who never had the disease. The findings, published Monday in Cancer, a journal of the American Cancer Society, highlight how physical activity can be a powerful tool for patients both during and after treatment.

Study Highlights the Impact of Exercise on Survival

While advances in cancer treatment have improved survival rates, people diagnosed with cancer still tend to have shorter lifespans compared to the general population. However, this study indicates that regular physical activity could help bridge that gap.

“After a colon cancer diagnosis, engaging in physical activity may help patients live longer, and for some, even as long as those without cancer,” said lead study author Dr. Justin Brown, associate professor at Louisiana State University’s Pennington Biomedical Research Center.

Researchers surveyed nearly 3,000 colon cancer patients about their exercise habits during and after chemotherapy. Over the course of six years, they analyzed survival rates and found that those who exercised regularly had a significantly lower risk of cancer recurrence and a longer lifespan.

How Exercise Fights Cancer

Though the study was observational—meaning it cannot definitively prove that exercise caused the improved survival rates—experts believe the connection is strong.

“Exercise improves heart health, mental health, and gut health, all of which play key roles in long-term survival,” said Dr. Keith Diaz, associate professor of behavioral medicine at Columbia University Medical Center.

Scientists believe physical activity helps in several ways:
Reduces inflammation – Lower inflammation levels can slow cancer growth.
Regulates insulin levels – High insulin can fuel cancer cell spread.
Strengthens the immune system – A stronger immune response helps the body detect and eliminate cancer cells.

Even Small Lifestyle Changes Matter

For colon cancer patients, making small but consistent changes in daily activity could have a significant impact.

“A small amount of physical activity each day may contribute to improved survival,” Brown emphasized. “Even little changes, when maintained over time, can make a big difference in health.”

The study found that five to six hours of moderate activity per week, such as brisk walking, was associated with longer survival. However, any level of movement is beneficial, even for those who aren’t currently active.

How Much Exercise is Enough?

The study raises important questions about the ideal type, intensity, and duration of exercise for cancer patients. Other recent research suggests:
1–2 minutes of vigorous activity (e.g., power walking, strenuous housework, or playing with kids) may reduce cancer risk.
11 minutes of moderate to vigorous exercise daily (e.g., jogging, cycling, swimming) may lower the risk of various diseases, including cancer.

A Message of Hope for Colon Cancer Survivors

Colorectal cancer is expected to become the leading cause of cancer-related deaths among 20- to 49-year-olds in the U.S. by 2030. However, this research offers hope: lifestyle changes, including regular physical activity, can make a real difference.

“A cancer diagnosis isn’t the end,” Diaz said. “There can be many healthy years ahead.”

Source

The post New Study: Physical Activity Boosts Survival for Colon Cancer Patients appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

In an exclusive interview, Dave Coulier, best known as Joey from Full House, shared that he’s been diagnosed with stage 3 non-Hodgkin lymphoma, a rare and aggressive cancer that affects white blood cells. Coulier, 65, learned of the diagnosis in October after an upper respiratory infection caused significant swelling in his lymph nodes.

The journey began with a swollen lymph node that grew to the size of a golf ball. Following advice from his doctor, Coulier underwent PET and CT scans and a biopsy. Within days, he received life-changing news: “I went from having a head cold to being told I have cancer. It was overwhelming, like a fast roller coaster ride,” Coulier recalled.

Non-Hodgkin lymphoma, according to the Mayo Clinic, causes abnormal growth of white blood cells, forming tumors throughout the body. Coulier’s specific type, B cell lymphoma, is rare and can affect the skin. With the diagnosis, Coulier and his wife Melissa, supported by friends in the medical field, immediately planned his treatment.

Positive Prognosis and Treatment Journey A hopeful moment came early when a bone marrow test returned negative, giving Coulier a 90% chance of cure. He started chemotherapy just two weeks after his diagnosis and shaved his head as a “preemptive strike.” Coulier opened up about his experience on his podcast Full House Rewind, saying, “I’m meeting this head-on and want to inspire others by sharing my journey.”

Determined to maintain a positive outlook for his family, including his wife Melissa and his son Luc, who is expecting his first child, Coulier draws strength from memories of family members who also battled cancer. “My mother, sister, and niece all faced cancer. I thought if I could be just a fraction as strong as they were, I’d be fine,” he reflected.

Support from Family and Humor to Stay Strong Coulier’s older sister Karen, also fighting cancer, has been a source of strength and humor throughout his journey. He shared light-hearted moments that have helped keep his spirits up, joking, “I’ve gone from a Virgo to a Cancer in weeks,” and referencing his love of hockey: “When they said I have NHL, I thought, ‘Finally made it to the NHL!’”

This blend of humor and resilience has helped Coulier stay calm. “When I first got the news, I was stunned, but an inner calm set in, perhaps inspired by the women in my family. They were magnificent in their battles, and they instilled that calm and strength in me,” he explained. “It’s been an incredible life with incredible people around me, and I’m at peace.”

Taking it Day by Day and Looking to the Future With one of six chemo treatments already completed, Coulier is navigating the ups and downs, from nausea and dizziness to days of renewed energy thanks to steroids. Recently, he took to the ice with friends in Detroit, a moment that reminded him of the joy in life. He’s also looking forward to becoming a grandpa, sharing, “I’ve got to teach him how to play hockey. There’s so much to look forward to.”

Coulier hopes his story will encourage others to prioritize their health. “Take care of yourself. Talk to your doctors, get screenings. It can make a huge difference in your life,” he advised.

Source

The post Dave Coulier Opens Up About Stage 3 Cancer Diagnosis: A Journey of Strength and Resilience appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.